Critical Survey: Genus (OTCMKTS:GENSF) and Kymera Therapeutics (NASDAQ:KYMR)

Genus (OTCMKTS:GENSFGet Free Report) and Kymera Therapeutics (NASDAQ:KYMRGet Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Earnings and Valuation

This table compares Genus and Kymera Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genus N/A N/A N/A $0.48 48.32
Kymera Therapeutics $78.59 million 27.87 -$146.96 million ($2.51) -14.22

Genus has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

29.7% of Genus shares are owned by institutional investors. 15.8% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Genus and Kymera Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Genus N/A N/A N/A
Kymera Therapeutics -194.67% -31.92% -23.98%

Analyst Recommendations

This is a summary of current recommendations and price targets for Genus and Kymera Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genus 0 0 0 0 N/A
Kymera Therapeutics 0 6 6 0 2.50

Kymera Therapeutics has a consensus price target of $41.10, suggesting a potential upside of 15.13%. Given Kymera Therapeutics’ higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than Genus.

Summary

Genus beats Kymera Therapeutics on 6 of the 10 factors compared between the two stocks.

About Genus

(Get Free Report)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.

About Kymera Therapeutics

(Get Free Report)

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.